ASSEMBLY BIOSCIENCES, INC.
ASMB · Pharmaceutical Preparations · 15.9M shares · -48%/yr ↓ buyback · EDGAR filings ↗
Reference price $23.25 · est. market cap ~$370M — last insider sale, 2026-06-17 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D48Antiviral biotech near breakeven on collaboration revenue (Gilead), with cash burn, funded.
Strengths
- Strong liquidity — current ratio 5.2 (60th)
- Major partnership (Gilead) revenue — per 10-K
Risks
- Near-breakeven/loss with cash burn — operating margin -17%, FCF -$41M
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Collaboration-dependence — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -8.5%)
- Cash burnNegative free cash flow (-41.2M)
- Buying back stockNet buyback — share count -48%/yr over 3y
- Strong balance sheetStrong balance sheet — $248M cash & investments, ~24 quarters of runway
- Insider sellingInsider selling — 5 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-16.8%
Net margin
-8.5%
Return on equity
-3.0%
Return on assets
-2.4%
Revenue growth (QoQ)
-9.4%
Current ratio
5.2×
Free cash flow
-$41M
EBITDA
-$12M
Tangible book value
$207M
Cash & investments
$248M
Cash runway
24q
Stock comp / revenue
6.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M | Sell | 29 | $23.25 |
| 2026-05-26 | GILEAD SCIENCES, INC. | Grant | 472K | $26.50 |
| 2026-03-30 | White Nicole S | Sell | 9 | $27.49 |
| 2026-03-30 | Bjorkquist Jeanette M | Sell | 312 | $26.65 |
| 2026-03-30 | Bjorkquist Jeanette M | Sell | 16 | $27.49 |
| 2026-03-30 | White Nicole S | Sell | 188 | $26.65 |
| 2026-03-29 | Okazaki Jason A | Grant | 51K | — |
| 2026-03-29 | White Nicole S | Grant | 14K | — |
| 2026-03-29 | Gaggar Anuj | Grant | 26K | — |
| 2026-03-29 | Delaney William E IV | Grant | 26K | — |
| 2026-03-29 | Okazaki Jason A | Grant | 94K | — |
| 2026-03-29 | Bjorkquist Jeanette M | Grant | 3.5K | — |
| 2026-03-29 | Delaney William E IV | Grant | 14K | — |
| 2026-03-29 | Bjorkquist Jeanette M | Grant | 6.5K | — |
| 2026-03-29 | Gaggar Anuj | Grant | 14K | — |
| 2026-03-29 | White Nicole S | Grant | 26K | — |
| 2025-08-08 | GILEAD SCIENCES, INC. | Buy | 2.3M | — |
| 2025-06-16 | Bjorkquist Jeanette M | Grant | 300 | — |
| 2025-03-31 | Okazaki Jason A | Sell | 355 | $9.85 |
| 2025-03-31 | White Nicole S | Sell | 197 | $9.85 |
| 2025-03-31 | McHutchison John G | Sell | 757 | $9.85 |
| 2025-03-31 | Bjorkquist Jeanette M | Sell | 180 | $9.85 |
| 2025-03-29 | Bjorkquist Jeanette M | Grant | 1.7K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-05 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-26 | Material agreementOtherExhibits | filing ↗ |
| 2026-05-22 | Reg FDOtherExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-03-30 | Exec/director changeExhibits | filing ↗ |
| 2026-03-19 | ResultsExhibits | filing ↗ |
| 2025-12-08 | Reg FDOtherExhibits | filing ↗ |
| 2025-11-10 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-05 | 2026-06-04 | 0001193125-26-259481 ↗ |
| 8-K | 2026-05-26 | 2026-05-21 | 0001193125-26-239277 ↗ |
| 8-K | 2026-05-22 | 2026-05-22 | 0001193125-26-235469 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-211922 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-211987 ↗ |
| 8-K | 2026-03-30 | 2026-03-24 | 0001193125-26-131872 ↗ |
| 8-K | 2026-03-19 | 2026-03-19 | 0001193125-26-115980 ↗ |
| 10-K | 2026-03-19 | 2025-12-31 | 0001193125-26-115992 ↗ |
| 8-K | 2025-12-08 | 2025-12-08 | 0001193125-25-311251 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001193125-25-274235 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001193125-25-274277 ↗ |
| 8-K | 2025-08-11 | 2025-08-08 | 0001193125-25-178092 ↗ |